MEDIPOST Co., Ltd.
Financials
Valuation Metrics
MEDIPOST Co., Ltd.'s Market Cap is ₩3477B. At end of 2025 it was ₩7131B. Ranked #596 of 2,421 in KR market (top 25%), #240 of 1,640 on KOSDAQ (top 15%), #15 of 96 in Health Care Equipment & Services (top 16%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 347.74B KRW | KR#596/2,421 Sec#15/96 |
| Revenue | 74.84B KRW | KR#1,584/2,421 Sec#44/96 |
| Net Income | -23.72B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 558.88B KRW | KR#721/2,421 Sec#11/96 |
| Net Assets | 273.68B KRW | KR#766/2,421 Sec#17/96 |
| Employees | 648 | KR#388/2,421 Sec#5/96 |
| Value | ||
| P/B | 1.27x | KR#1,667/2,421 Sec#55/96 |
| P/S | 4.65x | KR#2,131/2,421 Sec#72/96 |
| FCF Yield | -17.27% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -8.67% | KR#1,908/2,421 Sec#64/96 |
| ROA | -4.24% | KR#1,900/2,421 Sec#63/96 |
| Op. Margin | -102.23% | KR#2,303/2,421 Sec#85/96 |
| Revenue Growth | 3.70% | KR#1,281/2,421 Sec#66/96 |
| Financial Health | ||
| Debt Ratio | 104.21% | KR#1,598/2,421 Sec#81/96 |
| Total Debt | 158.44B KRW | KR#588/2,421 Sec#9/96 |
| FCF | -60.06B KRW | KR#2,097/2,421 Sec#83/96 |
| Cash | 78.36B KRW | KR#557/2,421 Sec#8/96 |
| Current Ratio | 1.27x | KR#1,428/2,421 Sec#73/96 |
| Performance | ||
| 1Y Return | -34.73% | KR#1,702/2,421 Sec#50/96 |
| 1M Return | -7.60% | KR#1,975/2,421 Sec#68/96 |
| From 52W High | -69.52% | KR#2,182/2,421 Sec#81/96 |
| 1Y MDD | -73.14% | KR#2,115/2,421 Sec#79/96 |
| Trading | ||
| Volume | 24,354 shares | KR#1,485/2,421 Sec#56/96 |
| Trading Value | 216.1M KRW | KR#1,246/2,421 Sec#48/96 |
| Foreign Own. | 2.32% | KR#1,516/2,421 Sec#54/96 |
| Per Share | ||
| EPS | -605 KRW | KR—/2,421 Sec—/96 |
| BPS | 6,981 KRW | KR#1,244/2,421 Sec#29/96 |
Company Info
Medipost, established in 2000 and listed on KOSDAQ in 2005, specializes in umbilical cord blood banking and stem cell therapy development. The company operates an umbilical cord blood bank, sells the degenerative arthritis treatment Cartistem, and develops umbilical cord blood-derived stem cell therapies. It also engages in the health functional food business, offering multivitamins and probiotics. Medipost is headquartered in Seongnam-si, Gyeonggi-do, and actively expands its market reach through awareness campaigns, global clinical trials for Cartistem, and diversified online marketing channels.